Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies
المؤلفون المشاركون
Bellocq, David
Mathis, Thibaud
Kodjikian, Laurent
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-16، 16ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-08-28
دولة النشر
مصر
عدد الصفحات
16
التخصصات الرئيسية
الملخص EN
Objectives of the Study.
Summary of observational studies concerning the pharmacological management of diabetic macular edema (DME).
Methods.
A literature review was conducted using the PubMed database on 1 February 2018 to identify studies evaluating the efficacy of anti-VEGF and dexamethasone (DEX) implants for DME.
Studies with more than 10 patients and follow-up of more than 6 months were selected.
Analyses were carried out on the overall population and on subgroups defined according to baseline visual acuity (BVA) and the patients’ naïve or non-naïve status.
Results.
Thirty-two studies evaluating the efficacy of anti-VEGF and 31 studies evaluating the efficacy of DEX-implants were retained, concerning 6,842 and 1,703 eyes, respectively.
A mean gain of +4.7 letters for a mean of 5.8 injections (mean follow-up: 15.6 months) and +9.6 letters for a mean of 1.6 injections (10.3 months) was found in the anti-VEGF and DEX-implant studies, respectively.
Final VA appears to be similar for both treatment (62 letters for anti-VEGF, 61.2 letters for DEX-implant), and BVA appears lower for DEX-implant, which may partially explain the greater visual gain.
The DEX-implant studies show greater gains in VA compared to the anti-VEGF studies, especially for higher BVA.
Indeed, mean gains for the subgroups of patients with BVA<50 letters, 50
Regarding the patient’s initial status, only naïve status appears to confer the best functional response in DEX-implant studies.
Conclusion.
Observational studies investigating DEX-implant report clinically similar final VA when compared to anti-VEGF, but superior visual gains in real-life practice.
This latter difference could be due to the better BVA, but also to the fact that less injections were administered in the anti-VEGF observational studies than in the interventional studies.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Kodjikian, Laurent& Bellocq, David& Mathis, Thibaud. 2018. Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies. BioMed Research International،Vol. 2018, no. 2018, pp.1-16.
https://search.emarefa.net/detail/BIM-1129029
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Kodjikian, Laurent…[et al.]. Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies. BioMed Research International No. 2018 (2018), pp.1-16.
https://search.emarefa.net/detail/BIM-1129029
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Kodjikian, Laurent& Bellocq, David& Mathis, Thibaud. Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies. BioMed Research International. 2018. Vol. 2018, no. 2018, pp.1-16.
https://search.emarefa.net/detail/BIM-1129029
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1129029
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر